233 related articles for article (PubMed ID: 15385832)
1. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation.
Kovarik JM; Tedesco H; Pascual J; Civati G; Bizot MN; Geissler J; Schmidli H
Ther Drug Monit; 2004 Oct; 26(5):499-505. PubMed ID: 15385832
[TBL] [Abstract][Full Text] [Related]
2. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.
Kovarik JM; Eisen H; Dorent R; Mancini D; Vigano M; Rouilly M; Hsu CH; Rordorf C
J Heart Lung Transplant; 2003 Oct; 22(10):1117-25. PubMed ID: 14550821
[TBL] [Abstract][Full Text] [Related]
3. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.
Kovarik JM; Kaplan B; Tedesco Silva H; Kahan BD; Dantal J; Vitko S; Boger R; Rordorf C
Transplantation; 2002 Mar; 73(6):920-5. PubMed ID: 11923693
[TBL] [Abstract][Full Text] [Related]
4. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
Kovarik JM; Snell GI; Valentine V; Aris R; Chan CK; Schmidli H; Pirron U
J Heart Lung Transplant; 2006 Apr; 25(4):440-6. PubMed ID: 16563975
[TBL] [Abstract][Full Text] [Related]
5. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.
Felipe CR; Oliveira NI; Hannun PG; de Paula MI; Tedesco-Silva H; Medina-Pestana JO
Ther Drug Monit; 2016 Feb; 38(1):64-72. PubMed ID: 26274696
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients.
Uchida K; Hoshinaga K; Watarai Y; Goto N; Kusaka M; Sasaki H; Hirano M;
Transplant Proc; 2014 Jun; 46(5):1314-8. PubMed ID: 24935294
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine minimization and cost reduction in renal transplant recipients receiving a C2-monitored, cyclosporine-based quadruple immunosuppressive regimen.
Hardinger KL; Schnitzler MA; Koch MJ; Enkvetchakul D; Desai N; Jendrisak M; Lowell JA; Miller B; Shenoy S; Brennan DC
Transplantation; 2004 Oct; 78(8):1198-203. PubMed ID: 15502720
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.
Rostaing L; Christiaans MH; Kovarik JM; Pascual J
Ann Transplant; 2014 Jul; 19():337-45. PubMed ID: 25017487
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
[TBL] [Abstract][Full Text] [Related]
11. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
13. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation.
Kovarik JM; Kaplan B; Silva HT; Kahan BD; Dantal J; McMahon L; Berthier S; Hsu CH; Rordorf C
Am J Transplant; 2003 May; 3(5):606-13. PubMed ID: 12752317
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with everolimus (Certican) in young renal transplant recipients.
Eris J
Transplantation; 2005 May; 79(9 Suppl):S89-92. PubMed ID: 15880023
[TBL] [Abstract][Full Text] [Related]
16. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data.
Pape L; Lehner F; Blume C; Ahlenstiel T
Transplantation; 2011 Sep; 92(6):658-62. PubMed ID: 21804444
[TBL] [Abstract][Full Text] [Related]
17. Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.
Ferraresso M; Belingheri M; Ginevri F; Murer L; Dello Strologo L; Cardillo M; Parodi A; Ghirardo G; Guzzo I; Innocente A; Ghio L
Pediatr Transplant; 2014 Jun; 18(4):350-6. PubMed ID: 24802342
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation].
Vavić N; Ignjatović L; Drasković B; Hrvacević R; Kovacević Z; Paunić Z
Vojnosanit Pregl; 2008 Feb; 65(2):119-27. PubMed ID: 18365668
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.
Lorber MI; Ponticelli C; Whelchel J; Mayer HW; Kovarik J; Li Y; Schmidli H
Clin Transplant; 2005 Apr; 19(2):145-52. PubMed ID: 15740547
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
Zhang Y; Zhang XD; Wang Y
Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
